Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Blood (2023) 142 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2023-182831

Published: 2023

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

Easix Indices Predict CRS and Overall Survival in Adult CAR-T Cell Recipients

Blood (2023) 142 (Supplement 1): 6905.

https://doi.org/10.1182/blood-2023-179506

Published: 2023

Journal Articles

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2023-187095

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus or Cyclosporine a and Mycophenolate Mofetil Compared to Anti-Thymocyte Globulin tacrolimus or Cyclosporine a and Methotrexate Combinations As Graft- versus -Host Disease Prophylaxis Post Allogeneic Stem Cell Transplantation from Sibling and Unrelated Donors in Patients with Acute Myeloid Leukemia: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2023-174821

Published: 2023

Journal Articles

Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide

Simona Piemontese, Myriam Labopin, Goda Choi, Annoek E.C. Broers, Ellen Meijer, Gwendolyn Van Gorkom, Montserrat Rovira, Maria Jesús Pascual, Simona Sica, Jan Vydra, Aleksander Kulagin, Alexandros Spyridonidis, Arnon Nagler, Ali Bazarbachi, Bipin N. Savani, Eolia Brissot, Jaime Sanz, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2023-182923

Published: 2023

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 2389–2391.

https://doi.org/10.1182/blood-2022-157890

Published: 2022

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Uwe Platzbecker, Emanuele Angelucci, Pau Montesinos, Roberto Massimo Lemoli, Alexandros Spyridonidis, Tariq I. Mughal, Carole Paley, Marcello Riggi, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 11710–11712.

https://doi.org/10.1182/blood-2022-160127

Published: 2022

Journal Articles

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Rama Al Hamed, Myriam Labopin, Wolfgang Bethge, Arnold Ganser, Arne Brecht, Johanna Tischer, Nicolaus Kröger, Donald Bunjes, Hermann Einsele, Mareike Verbeek, Igor Wolfgang Blau, Martin Kaufmann, Eolia Brissot, Ali Bazarbachi, Christoph Schmid, Alexandros Spyridonidis, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 10455–10457.

https://doi.org/10.1182/blood-2022-170244

Published: 2022

Journal Articles

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2022) 140 (Supplement 1): 2110–2112.

https://doi.org/10.1182/blood-2022-162277

Published: 2022

Journal Articles

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Uwe Platzbecker, Emanuele Angelucci, Pau Montesinos, Roberto M. Lemoni, Alexandros Spyridonidis, Joaquín Casariego, Tariq I. Mughal, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 5032.

https://doi.org/10.1182/blood-2021-145099

Published: 2021

Journal Articles

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Blood (2021) 138 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2021-145100

Published: 2021

Journal Articles

Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Blood (2021) 138 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2021-146303

Published: 2021

Journal Articles

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Blood (2021) 138 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2021-151000

Published: 2021

Journal Articles

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

Xavier Thomas, MD PhD, Anita W Rijneveld, MD PhD, Nicola Fracchiolla, MD, Cyril Šálek, MD, Alexandros Spyridonidis, MD PhD, Sabina Chiaretti, MD PhD, Naufil Alam, PhD, Isabella Pezzani Grueter, PharmD, Abeera Mohammad, MSc, William Kormany, MD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134470

Published: 2020

Journal Articles

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136940

Published: 2020

Journal Articles

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Alexandros Spyridonidis

Blood (2020) 135 (19): 1639–1649.

https://doi.org/10.1182/blood.2019003566

Published: 2020

Journal Articles

The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 43.

https://doi.org/10.1182/blood-2019-123310

Published: 2019

Journal Articles

Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As "Reduced-Toxicity" Conditioning for Patients with Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT

Sebastian Giebel, MD PhD, Myriam Labopin, MD, Malgorzata Maria Sobczyk Kruszelnicka, MD, Matthias Stelljes, Jenny Byrne, MD PhD, Nathalie Fegueux, MD, Dietrich W. Beelen, Montserrat Rovira, Alexandros Spyridonidis, MD PhD, Didier Blaise, MD PhD, Martin Bornhäuser, MD, Ihsan Karadoğan, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 255.

https://doi.org/10.1182/blood-2019-129993

Published: 2019

Journal Articles

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Blood (2019) 134 (Supplement_1): 4913.

https://doi.org/10.1182/blood-2019-125343

Published: 2019

NARROW

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Easix Indices Predict CRS and Overall Survival in Adult CAR-T Cell Recipients

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation

Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As "Reduced-Toxicity" Conditioning for Patients with Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only